PBAC's latest decision on Rivaroxaban: Noted (2024). Considered for New pack sizes (2.5 mg 98-pack and 10 mg 14-pack) for existing indications: chronic stable atherosclerotic disease (chronic coronary artery disease and/or peripheral artery disease) for the 2.5 mg strength, and prevention of venous thromboembolism in total hip or knee replacement for the 10 mg strength.
PBAC outcome
Noted
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
10
first 2009
Submissions
10
2009 → 2024
Eligible population
Patients with chronic stable atherosclerotic disease (chronic coronary artery disease and/or peripheral artery disease) for the 2.5 mg strength; patients undergoing total hip or knee replacement for the 10 mg strength.
Cost-minimisation analysis only; no ICER calculated. Submission based on cost-per-tablet comparison of new pack sizes to existing pack sizes.
ICER (historical)
$15k/QALY–$45k/QALY across 5 submissions (2009–2020) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Mar 2009: Recommended · Authority Required — ICER $75k/QALY
Mar 2012: Recommended with restriction — ICER $45k/QALY
Nov 2012: Not recommended — ICER $15k/QALY
Mar 2013: Recommended with restriction · Authority Required
Mar 2013: Not recommended · Authority Required — ICER $15k/QALY
Nov 2018: Recommended with restriction · Authority Required
Mar 2019: Deferred · Authority Required
Mar 2020: Recommended with restriction · Authority Required